Microsoft

Let’s Get Digital! A look at ��ֳ�’s digital transformation in R&D

Vanco Vlastimil (��ֳ� S.A.) — Wed, 30 Mar 2022 11:22:17 +0000

Let’s Get Digital! A look at ��ֳ�’s digital transformation in R&D

Lévina Caufriez, Research & Development Communications

Vanco Vlastimi… Wed 30/03/2022 - 13:22

Around the world, technology is changing how patients experience healthcare, how healthcare professionals practice medicine, and how pharmaceutical companies like ours conduct research and provide medicines to those who need them. Research and development is at the very heart of what we do here at ��ֳ�, and we are amplifying the power of scientific innovation through digitalisation to create sustainable value, ensuring that patients get the solutions they need and can live the lives they choose.

Creating patient value in a digital age

At ��ֳ�, our central mission is to deliver value for people living with severe immunological and neurological diseases now and into the future. To do this, we've recognised that leveraging digital technology throughout the business is not just a choice but a necessity; it allows us to think outside the box and create transformative projects that meet patients where they are. Our Digital Care Transformation (DCTx) approach aims to use data and technology with purpose throughout the whole value chain, for both drug and non-drug solutions, as we know patient value extends beyond the molecule.

Today’s patients consider themselves as active participants in their care journey; they are increasingly demanding more personalised and convenient healthcare solutions. To meet these demands, we’re creating digital initiatives that unlock holistic, personal and efficient value – generating value for patients from more than just drugs.

Embracing digital business transformation to accelerate solutions

��ֳ� is making strides through digital business transformation to boost the efficiency and effectiveness of our operations, creating new – or modifying existing – processes and tools to deliver additional value for patients and stakeholders.

Discovery

In drug discovery, we’re implementing digital business transformation initiatives with the aim of increasing the speed at which we deliver solutions to patients. The ��ֳ� Moonshot effort, developed in partnership with PostEra – a start-up biotech company that maps routes for drug synthesis using AI algorithms – is working to test and refine crowdsourced drug designs, sourced from medicinal chemists, to develop an anti-viral treatment for COVID-19.

The initiative is not only providing better research data-driven insights to fast-track the discovery of therapeutic molecules and improve patient journeys, but also helping to find “pockets” that may not have been seen before and re-envision “undruggable targets”.

Efficiency

The last decade has introduced new computational methods which increase the cost-effectiveness and efficiency in the pharmaceutical industry. The digitalisation of patient records and clinical trials, the advent of cloud computing, the growth of wearable devices and the medical Internet of Things (mIoT) has transformed clinical development with an explosion of data.

In development phase, our Statistical Science & Innovation group at ��ֳ�, recently filed a patent application centred around an improved machine learning method. The application has been designed to search through a large hypothesis space to identify the most valuable pieces of information and allows AI to predict an outcome or provide decision guidance. This innovation has already been used to inform patient stratification, clinical trial design and precision medicine approaches for Parkinson’s disease and epilepsy.

Being Data-Enabled

At ��ֳ� we use data analysis to answer questions and inform better decisions on behalf of patients and caregivers, which has had a tremendous impact on how we work, as well as how efficiently we can deliver results. For example, the use of analytics and machine learning throughout our drug discovery, development, and innovation processes means we can optimise the way clinical trials are designed. This includes patient selection, automated analysis of trial data and enhanced logistics operations. All this work is expanding, allowing ��ֳ� to build a platform to maximise the value of our data for patients.

Connected

Collaboration is an important component of innovation and scientific breakthroughs within ��ֳ�, which is why we partnered with several of the top digital health companies in 2021.

One key example is our partnership with Microsoft, which combines our deep knowledge in bioscience with Microsoft’s unmatched expertise in computer science and artificial intelligence (AI) to reinvent how we create new medicines. The ambition is to establish a 360° data-enabled view of patient populations to discover and develop medicines faster for people living with severe diseases. This collaboration opportunity with Microsoft will provide AI technology to work alongside ��ֳ�’s scientists and data specialists, to break boundaries and allow ��ֳ� to discover new correlations and patterns critical to finding innovative and highly individualized medicines.

At ��ֳ� we are committed to refining and evolving our digital research and development strategy with partners and collaborators, to best serve patients who are the driving force of our motivation for all that we do. The opportunity and challenge is to be continuously innovating and intensely curious as industry leaders to create patient value in the digital age.

about ucb

818 Likes

Partnering for Greater Impact with Microsoft in R&D

Vanco Vlastimil (��ֳ� S.A.) — Wed, 23 Feb 2022 10:02:30 +0000

Partnering for Greater Impact with Microsoft in R&D

Wang Yuan, Data and Translational Sciences

Vanco Vlastimi… Wed 23/02/2022 - 11:02

At ��ֳ�, our aim is to amplify the power of scientific innovation through digital transformation, ensuring we deliver the best individual experience so patients can live their best lives. As part of that effort, we are integrating artificial intelligence (AI) across the research and development organization to bring accelerated solutions to patients with unmet needs.

In drug discovery, specifically, we’re using AI methodologies to enhance ��ֳ�’s data science strategy. We want to increase the impact of a treatment through a deeper understanding of the biological causes of the disease and systematically provide better research data-driven insights to enable the faster discovery of therapeutic molecules.

To aid us in this research, we announced an expanded multi-year, strategic collaboration to combine Microsoft’s computational services, cloud, and AI with ��ֳ�’s drug discovery and development capabilities. As several drug discovery activities require the analysis of high-dimensional data sets or multi-modal unstructured information, Microsoft’s platform can support ��ֳ�’s scientists, including its data scientists, to discover new medicines in a more efficient and innovative way.

Our first use case is related to our Targeted Protein Degradation platform, where we are using AI-enabled workflows to better and more quickly collect information around disease-relevant biology and potential molecules of therapeutic value. Supported by Microsoft’s data science capabilities, our researchers aspire to ask questions on a whole new scale, and to review and compare millions of scientific literature in a more efficient manner.

By using advanced analytics, researchers can analyze and synthesize decades of scientific knowledge faster, with better interconnectivity to uncover underlying trends. Based on such extensive knowledge, scientists can make more informed data-driven decisions in the search of new medicines.

In addition to the scientific journey we have started here, this collaboration is also a cultural journey, exposing our industry to the novel solutions and enabling technologies provided by our partners in the technology sector, and inviting our partners to tackle more scientific challenges we face.

Watch the video now.

We are deepening our impact for people living with severe diseases by finding the right medicine for the right patient at the right time and working to further the good of society with a comprehensive collaboration strategy to support innovation. We are forging new relationships with leading researchers from academia and organizations, like Microsoft, to address some of today’s biggest healthcare challenges.

about ucb

Microsoft AI Artificial Intelligence Drug discovery R&D

982 Likes

Embracing Digital Business Transformation to Accelerate Tailored Solutions for Patients

eCMSadmin — Fri, 05 Mar 2021 13:00:00 +0000

Embracing Digital Business Transformation to Accelerate Tailored Solutions for Patients

Emmanuel Caeymaex, Patient Value Immunology ＆ US Solutions

eCMSadmin Fri 05/03/2021 - 14:00

��ֳ�’s ambition is to provide patients with unique outcomes, to ensure they have access to the solutions they need, and to deliver the best individual experience. In a world where digital technology is significantly changing the way patients experience their care, how healthcare professionals practice medicine, and how companies like ��ֳ� discover and develop solutions and bring them to patients, this ambition is both being challenged and encouraged. All of this has been accelerated by the pandemic.

Our approach to this digital business transformation essentially focuses on selectively applying advanced analytics and digital engagement tools, at scale, and on developing digital care solutions for multisided digital platform ecosystems to transform the patient experience. We also believe in partnering with pioneers at the forefront of technology and data-powered innovation for greater impact to help drive our healthcare system’s evolution further. Together, we are accelerating research and development cycles and digitalizing our operations to meet our customers where they are while helping patients live their best lives, whatever that means for them.

Discovery
In drug discovery, we are using computational design and artificial intelligence to more efficiently identify compounds that have a higher chance of leading to effective therapies. We’re working hard to increase the impact of a treatment through a deeper understanding of the biological causes of disease, systematically provide better research data-driven insights to enable the faster discovery of therapeutic molecules, and improve a patient’s overall journey.

As part of that work, we recently entered a new multi-year, strategic collaboration with Microsoft, to combine their Artificial Intelligence (AI) technologies and cutting-edge platforms to discover and develop new medicines in a more efficient and innovative way.

Development
In the development of new medicines, we digitalize our clinical study protocols and have provided decentralized clinical trials, which have resulted in the continuity of patient care through remote visits even during the COVID-19 pandemic. Gaining real-time access to patient feedback enrolled in our clinical trials is important to us, and we often use patient experience surveys to help us better understand the patient experience. For one of our key assets, the results were outstanding, with a NPS score of 53, far exceeding the industry benchmark of 22 specific to the indication. This tells us we are on the right track with enhancing the patient’s overall experience as they embark on this important part of their health care journey.

Go-to-Market and Digital Care Transformation
In the delivery of medicines and solutions to the market, we’ve expanded our use and mix of distinctive channels and of predictive analytics to generate a better, more tailored, experience for our customers. This has become even more important during the pandemic as we understand changing physician needs. We have been reimagining frontline ways of working in several markets, with eager adoption of new tools by our colleagues in the field. This promises to result in more fulfilling work, a leading capability, and an increasingly effective go-to-market model.

We also recently announced the launch of Nile AI, Inc., a new independent company created to improve care for people living with epilepsy, their caregivers, and healthcare providers. Nile is developing an epilepsy care management platform that serves as a digital extension of the healthcare provider and provides patients with peace of mind between consultations, with the ultimate goal of shortening the path to optimal care.

Partnering for Impact
As we continue to transform the way care is delivered, we believe that partnering can make a greater impact. Our collaboration with MyHealthTeams, an organization that creates social networks for people living with chronic conditions, has enabled us to contribute to their well-being and access to information and to gain insights into their experience of learning, treating and and coping with their disease. For instance, the MySpondylitisTeam, which focuses on spondyloarthritis, is an active patient community started in early 2018 with more than 42,000 members.

Through our work with Ali Health in China, a digital healthcare provider, we’re also exploring an innovative service model for the intelligent management of chronic diseases like epilepsy. As the first step of the strategic agreement, ��ֳ� has created an "Epilepsy Care on Alipay" account on the Alipay app to serve epilepsy patients and provide cloud-based diagnosis, treatment, and medication delivery to improve the overall patient experience.

Partnering has been central to building and scaling target digital capabilities and delivering promising results rapidly, to further support this journey of change. In many cases, we decided to pair our knowledge of a patient population with the acumen and capabilities of digital health players.

The rapid integration of digital innovation into all aspects of our business is a testament to how quickly we can adapt to the needs of patients and the ever-changing environment. Much of this stems from the size of ��ֳ� – large enough to make an impact, but small enough to remain agile. This agility provides greater opportunities for our employees to engage in work that is more creative, strategic, and transversal, and which better delivers on our goal of developing personalized experiences for people living with severe diseases.

To achieve these ambitious goals, ��ֳ� is advancing how we work and embracing our key organizational enablers of success: by unleashing the power of data; by rapidly gaining digital capabilities; and most importantly, evolving our culture and how our people approach work, by eliminating barriers to customer-centricity, being bold in our adaptability with transversal collaboration and experimentation. By empowering individuals with decision-making and an entrepreneurial mindset that flourishes within an agreed frame , we can amplify the power of scientific innovation through digital transformation, creating sustainable value, and ensuring that patients can live the lives they choose now and in the future.

about ucb

DBT Nile AI MyHealthTeams Microsoft digital business transformation Ali Health AI

932 Likes

Microsoft

Let’s Get Digital! A look at ��ֳ�’s digital transformation in R&D

Leave a Comment

Partnering for Greater Impact with Microsoft in R&D

Leave a Comment

Embracing Digital Business Transformation to Accelerate Tailored Solutions for Patients

Leave a Comment

Microsoft

Let’s Get Digital! A look at ������ֳ�’s digital transformation in R&D

Leave a Comment

Partnering for Greater Impact with Microsoft in R&D

Leave a Comment

Embracing Digital Business Transformation to Accelerate Tailored Solutions for Patients

Leave a Comment

Let’s Get Digital! A look at ��ֳ�’s digital transformation in R&D